MYGN - MYRIAD GENETICS INC
IEX Last Trade
13.74
-14.730 -107.205%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$28.47
-14.73
-51.74%
Fundamental analysis
4%
Profitability
0%
Dept financing
9%
Liquidity
27%
Performance
1%
Performance
5 Days
2.84%
1 Month
-12.54%
3 Months
-47.34%
6 Months
-44.28%
1 Year
-32.32%
2 Year
-10.61%
Key data
Stock price
$13.74
DAY RANGE
$13.42 - $28.47
52 WEEK RANGE
$13.39 - $29.30
52 WEEK CHANGE
-$30.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Paul J. Diaz
Region: US
Website: myriad.com
Employees: 2,600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: myriad.com
Employees: 2,600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.
Recent news